BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 15.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,742 shares of the medical equipment provider’s stock after purchasing an additional 3,482 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned 0.06% of ABIOMED worth $11,577,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in ABMD. NEXT Financial Group Inc bought a new position in ABIOMED in the third quarter valued at approximately $115,000. Migdal Insurance & Financial Holdings Ltd. increased its stake in ABIOMED by 160.2% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 320 shares of the medical equipment provider’s stock valued at $144,000 after acquiring an additional 197 shares during the last quarter. TRUE Private Wealth Advisors bought a new position in ABIOMED in the third quarter valued at approximately $162,000. OLD Mutual Customised Solutions Proprietary Ltd. bought a new position in ABIOMED in the second quarter valued at approximately $164,000. Finally, Rampart Investment Management Company LLC acquired a new stake in ABIOMED in the second quarter valued at approximately $175,000. 87.27% of the stock is currently owned by institutional investors.
A number of analysts have weighed in on the stock. ValuEngine upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a research report on Wednesday, November 28th. BidaskClub lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Thursday, November 15th. BTIG Research upgraded shares of ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 target price on the stock in a research report on Friday, November 2nd. Finally, Morgan Stanley raised their target price on shares of ABIOMED from $370.00 to $396.00 and gave the company an “equal weight” rating in a research report on Thursday, October 11th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $402.78.
Shares of ABIOMED stock opened at $327.18 on Thursday. ABIOMED, Inc. has a fifty-two week low of $186.72 and a fifty-two week high of $459.75. The company has a market capitalization of $14.74 billion, a price-to-earnings ratio of 105.88, a P/E/G ratio of 2.67 and a beta of 0.28.
ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.36. The company had revenue of $181.78 million for the quarter, compared to analyst estimates of $175.41 million. ABIOMED had a net margin of 27.60% and a return on equity of 20.09%. ABIOMED’s revenue was up 36.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.54 earnings per share. Equities research analysts expect that ABIOMED, Inc. will post 3.57 EPS for the current fiscal year.
In other news, VP Michael G. Howley sold 10,000 shares of ABIOMED stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $432.50, for a total transaction of $4,325,000.00. Following the transaction, the vice president now owns 48,954 shares in the company, valued at $21,172,605. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 3.50% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/12/06/british-columbia-investment-management-corp-acquires-3482-shares-of-abiomed-inc-abmd.html.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Featured Article: Why is the ex-dividend date different from the record date?
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.